drugset / Trial / NCT02197598

Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use

NCT02197598

Phase 4 Completed 45 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the treatment effects of Selincro in alcohol dependent patients with liver impairment.

Timeline

Start
2014-09
Primary completion
2015-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nalmefene Small molecule 18 mg Oral

Indications